Physician profile
Jacquelyn D Levy
NPI 1730573049
$6,886.84
in general payments reported to CMS, 2019-2025
25 companies · $1,546 in 2025
The $1,546 reported for 2025 was more than what 85% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $287 · 2020: $715 · 2021: $973 · 2022: $1,507 · 2023: $631 · 2024: $1,229 · 2025: $1,546.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,405.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,404.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,423.19 | 2019-2025 | Clareon, Clareon Panoptix Pro, Argos |
| Abbvie INC. | $666.38 | 2022-2025 | Durysta |
| Sun Pharmaceutical Industries INC. | $426.94 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $405.03 | 2022-2025 | Envista Mx60 Iol, Miebo, Xiidra |
| Allergan, INC. | $383.09 | 2019-2022 | |
| Oyster Point Pharma, INC. | $338.80 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Eyevance Pharmaceuticals LLC | $305.06 | 2020-2021 | |
| Sight Sciences, INC. | $300.56 | 2019-2024 | Omni Surgical System |
| New World Medical,INC. | $255.94 | 2022-2025 | Clearpath, Streamline, Ahmed Glaucoma Valve |
| Mallinckrodt Hospital Products INC. | $234.43 | 2021-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $194.45 | 2020-2021 | |
| Dompe US, INC. | $152.83 | 2021-2025 | Oxervate |
| Harrow Eye, LLC | $136.85 | 2024-2025 | Vevye |
| Tarsus Pharmaceuticals, INC. | $94.15 | 2024-2025 | Xdemvy |
| Topcon Healthcare, INC. | $83.41 | 2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akorn, INC. | $81.54 | 2020 | |
| Johnson & Johnson Surgical Vision, INC. | $81.11 | 2019-2025 | Tecnis Iol |
| Amgen INC. | $72.64 | 2025 | Tepezza |
| Biotissue Holdings INC. | $55.64 | 2025 | |
| Aerie Pharmaceuticals, INC. | $50.01 | 2020-2021 | |
| Kala Pharmaceuticals, INC. | $40.71 | 2019-2020 | |
| Thea Pharma INC. | $32.53 | 2024-2025 | Iyuzeh |
| Novartis Pharmaceuticals Corporation | $26.50 | 2021-2022 | |
| Apellis Pharmaceuticals, INC. | $23.97 | 2025 | Syfovre |
| Rxsight INC | $21.08 | 2024 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacquelyn Levy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.